Grace Therapeutics, Inc. Schedule 13G/A (Amendment No. 4) reports that AIGH Capital Management LLC, AIGH Investment Partners LLC and Orin Hirschman jointly beneficially own 814,000 shares of Common Stock, representing 4.9% of the class. The filing states the 814,000 shares include 814,000 common shares issuable upon exercise of warrants and exclude 10,742 common shares issuable upon exercise of warrants not currently exercisable due to beneficial ownership limitations on exercise.
Positive
None.
Negative
None.
Insights
Joint 13G/A shows warrant-based stake near the 5% threshold.
The filing lists 814,000 shares beneficially owned, described as entirely issuable upon exercise of warrants. The reported 4.9% position sits just below the 5% reporting threshold, with 10,742 warrants currently excluded due to a "beneficial ownership limitations on exercise" clause.
Watch subsequent amendments: if warrants become exercisable or additional purchases occur, the ownership percentage could cross the 5% reporting level and require further disclosure.
Key Figures
Reported beneficial ownership:814,000 sharesPercent of class:4.9%Excluded warrant shares:10,742 shares
Percent of class4.9%Percent of Common Stock beneficially owned
Excluded warrant shares10,742 sharesShares issuable on warrants not currently exercisable due to beneficial ownership limitations on exercise
Key Terms
beneficially owned, beneficial ownership limitations on exercise, warrants issuable upon exercise
3 terms
beneficially ownedregulatory
"Includes 814,000 common shares issuable upon exercise of warrants"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
beneficial ownership limitations on exerciseregulatory
"not currently exercisable due to beneficial ownership limitations on exercise"
warrants issuable upon exercisefinancial
"Includes 814,000 common shares issuable upon exercise of warrants"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 4)
Grace Therapeutics, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
00439U104
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
00439U104
1
Names of Reporting Persons
Orin Hirschman
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
814,000.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
814,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP Number(s):
00439U104
1
Names of Reporting Persons
AIGH Capital Management LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
814,000.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
814,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.9 %
12
Type of Reporting Person (See Instructions)
IA, OO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Grace Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
103 Carnegie Center, Suite 300, Princeton, NJ, 08540
Item 2.
(a)
Name of person filing:
This Schedule 13G is being jointly filed by each of the following persons pursuant to Rule 13d-1 promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the "Act"):
(i) AIGH Capital Management, LLC, a Maryland limited liability company ("AIGH CM"), as an Advisor or Sub-Advisor with respect to shares of Common Stock (as defined in Item 2(d) below) held by AIGH Investment Partners, L.P., and WVP Emerging Manger Onshore Fund, LLC - AIGH Series.
(ii) AIGH Investment Partners, L.L.C., a Delaware limited liability company ("AIGH LLC";), with respect to shares of Common Stock (as defined in Item 2(d) below) directly held by it;
(iii) Mr. Orin Hirschman ("Mr. Hirschman"), who is the Managing Member of AIGH Capital Management, LLC and president of AIGH LLC, with respect to shares of Common Stock (as defined in Item 2(d) below) indirectly held through AIGH CM, directly by AIGH LLC and Mr. Hirschman and his family directly.
AIGH Capital Management LLC., AIGH Investment Partners LLC, and Mr. Hirschman are hereinafter sometimes collectively referred to as the "Reporting Persons." Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
(b)
Address or principal business office or, if none, residence:
The principal office and business address of AIGH Capital Management LLC, AIGH Investment Partners LLC, and Mr.Hirschman is: 6006 Berkeley Avenue, Baltimore MD 21209
(c)
Citizenship:
See Item 2(a) above and Item 4 of each cover page.
(d)
Title of class of securities:
Common Stock
(e)
CUSIP No.:
00439U104
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
814,000
Includes 814,000 common shares issuable upon exercise of warrants and excludes 10,742 common shares issuable upon exercise of warrants not currently exercisable due to beneficial ownership limitations on exercise
(b)
Percent of class:
4.9 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
814,000
Includes 814,000 common shares issuable upon exercise of warrants and excludes 10,742 common shares issuable upon exercise of warrants not currently exercisable due to beneficial ownership limitations on exercise
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What stake does AIGH and Orin Hirschman report in GRCE?
They report beneficial ownership of 814,000 shares, representing 4.9% of Grace Therapeutics' common stock. The filing says those shares include 814,000 shares issuable upon exercise of warrants and excludes 10,742 shares not currently exercisable.
Why are 10,742 shares excluded from the reported ownership?
The 10,742 common shares are excluded because they are issuable upon exercise of warrants that are not currently exercisable due to beneficial ownership limitations on exercise. The filing cites that specific limitation as the reason for exclusion.
Does the filing indicate who filed the Schedule 13G/A for GRCE?
Yes. The filing is jointly made by AIGH Capital Management LLC, AIGH Investment Partners LLC, and Orin Hirschman, identified as the reporting persons and described in Item 2 of the filing with the listed principal business address.
Are the reported shares common stock or another instrument?
The filing states the holdings are in Common Stock. It specifies that 814,000 shares are issuable upon exercise of warrants, indicating the position is tied to warrant exercises converting into common stock.
Does this filing push ownership over the 5% threshold for GRCE?
No. The filing reports a 4.9% beneficial ownership stake. The reported total excludes 10,742 shares currently not exercisable; if those became exercisable or additional purchases occurred, the percentage could change and trigger further disclosure.
